Mission Creek Capital Partners Inc. Sells 126 Shares of Stryker Co. (NYSE:SYK)

Mission Creek Capital Partners Inc. cut its position in Stryker Co. (NYSE:SYK) by 2.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,744 shares of the medical technology company’s stock after selling 126 shares during the quarter. Mission Creek Capital Partners Inc.’s holdings in Stryker were worth $2,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in SYK. Centennial Bank AR grew its position in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after buying an additional 48 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Stryker in the third quarter worth approximately $36,000. HBW Advisory Services LLC purchased a new stake in Stryker in the third quarter valued at approximately $42,000. Hara Capital LLC bought a new stake in Stryker during the third quarter valued at approximately $42,000. Finally, Grove Bank & Trust increased its holdings in shares of Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 0.3 %

NYSE SYK opened at $390.97 on Wednesday. The firm has a market capitalization of $149.04 billion, a PE ratio of 41.90, a P/E/G ratio of 2.94 and a beta of 0.94. The stock’s 50 day moving average is $369.58 and its 200 day moving average is $352.53. Stryker Co. has a twelve month low of $285.79 and a twelve month high of $398.20. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the business posted $2.46 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Activity

In other news, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,781 shares of company stock worth $24,612,275. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SYK shares. Wells Fargo & Company increased their price target on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Royal Bank of Canada lifted their price objective on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $370.00 to $445.00 in a report on Monday. Needham & Company LLC lifted their price target on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Evercore ISI increased their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $398.40.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.